Aciont's Paper, "Transscleral Iontophoresis for Noninvasive Ocular Drug Delivery of Macromolecules" Published in JOPT
Aciont Inc. announced today that results from preclinical studies of its Visulex-I technology is published online ahead of print in the Journal of Ocular Pharmacology and Therapeutics under the title “Transscleral Iontophoresis for Noninvasive Ocular Drug Delivery of... - April 18, 2020
Aciont Issued Key Patent Covering the Novel Design of the Visulex Ocular Drug Delivery Device
Aciont was issued a U.S. patent that covers an important aspect of the novel design of its main Visulex ocular drug delivery system which has been tested for safety and efficacy in its lead clinical program under U.S. IND. - October 12, 2019
Clinical Safety and Efficacy Data of DSP-Visulex Published in Current Eye Research
Aciont Inc. announced today that data from the clinical study of the DSP-Visulex technology is published online ahead of print in Current Eye Research. Reference: Papangkorn K, Truett KR, Vitale AT, Jhaveri C, Scales DK, Foster CS, Montieth A, Higuchi JW, Brar B, Higuchi WI. Novel dexamethasone sodium phosphate treatment (DSP-Visulex) for noninfectious anterior uveitis: a randomized phase I/II clinical trial. Current Eye Research. - December 06, 2018
Aciont to Present Phase 1/2 Clinical Data at ARVO 2018 Annual Meeting
Aciont Inc. announced today that Dr. Kongnara Papangkorn, VP of Product Development, will be presenting clinical data of Aciont’s lead product, DSP-Visulex, from its phase 1/2 clinical trial in the treatment of noninfectious anterior uveitis (DSPV-201) at the Association for Research in... - March 10, 2018
Aciont® To Present on VisulexTM Technologies at the 4th Ocular & Drug Discovery Conference
Aciont Inc. announced today that both Kongnara Papangkorn, Research Director and Sarah Abdulla Molokhia, Scientific Research Consultant, will present on Aciont’s Visulex technologies at the Global Technology Community’s 4th Ocular & Drug Discovery Conference, February 27-28, 2012,... - January 12, 2012
Aciont® to Present at the 13th Annual NIH SBIR/STTR Conference
Dr. Kongnara Papangkorn’s presentation is entitled, “Safety Aspects and Drug Delivery Performance of Visulex® Passive Delivery System” - June 09, 2011
Aciont® CEO to Present at IN3 West Medical Device Conference
John Higuchi will present on behalf of Aciont Inc at the IN3 West Medical Device Conference in Las Vegas, NV on February 22, 2011. - February 10, 2011
Aciont® Awarded Two Qualifying Therapeutic Discovery Project Grants Totaling $489K
Aciont Inc. announced today that it has been awarded $488,958 to support two projects under the U.S. Government’s Qualifying Therapeutic Discovery Project (QTDP) program. Aciont submitted only the following two applications to the program of which both were funded at the maximum allocation... - November 05, 2010
The NIH Awards Aciont® a Small Business Catalyst Award Grant Accelerating Innovative Research
Aciont is awarded a phase I SBIR $214K grant for the project titled “Novel Method for the Ocular Iontophoretic Delivery of Avastin® and Lucentis®.” - July 08, 2010
NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont®
The National Eye Institute (NEI) awarded a $2.18 million grant to Aciont Inc. to help fund its development of a non-invasive, passive diffusion-based treatment for severe, non-infectious uveitis. - December 12, 2009